Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2019-12-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于药品获得临床试验默示许可的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the receipt of an implicit clinical trial approval from the National Medical Products Administration for a new drug. It contains no financial data, no detailed financial statements, nor any regulatory certifications or officer attestations. The content is a regulatory announcement about a clinical trial approval, which is a typical regulatory filing. The document length is short (891 characters), and it is not a report or presentation but an official announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS).
2019-12-09 Chinese
关于监事会换届选举的提示性公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding the upcoming election and reconstitution of the Supervisory Board (监事会) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It outlines the procedures, candidate qualifications, nomination process, and related administrative details for the Supervisory Board election. There is no financial data, earnings information, or report publication mentioned. The content focuses on governance and management structure changes, specifically about the Supervisory Board election process. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management bodies.
2019-12-04 Chinese
关于董事会换届选举的提示性公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding the upcoming board of directors election for Shenzhen Xinlitai Pharmaceutical Co., Ltd. It outlines the composition of the new board, the election procedures, qualifications for directors, and the nomination process. It includes legal references and procedural details but does not contain financial data or results. The document is clearly about management and board changes, specifically the board re-election process. It is not a financial report, earnings release, or regulatory filing of financial results. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4100 characters, which is consistent with an announcement rather than a full report. Confidence is high due to the explicit focus on board election and management changes.
2019-12-04 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, prices, compliance with regulations, and future plans for the buyback. It does not contain financial statements or comprehensive financial data but rather updates on the share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares.
2019-12-01 Chinese
关于阿利沙坦酯纳入医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1063 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the inclusion of their drug Alisartan in the national medical insurance catalog. It references a government notice and provides details about the drug's pricing and agreement period. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is an official announcement about a regulatory or market event affecting the company, not a full report or detailed financial disclosure. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Report. It is also not a certification or insider dealing report. Given the nature and length, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-11-28 Chinese
关于首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase (buyback) plan and execution details. It includes specifics about the number of shares repurchased, prices, compliance with relevant laws and stock exchange rules, and future intentions to continue the repurchase plan. The document does not contain financial statements or detailed financial analysis but focuses on the share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company buying back its own shares.
2019-11-12 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.